- BriaCell Therapeutics (TSX:BCT) will present positive clinical data of Bria-IMT at the 2024 American Society of Clinical Oncology in Chicago
- The clinical-stage biotechnology company is presenting updated clinical data of its randomized Phase 2 study evaluating its lead product candidate, Bria-IMT in patients with advanced metastatic breast cancers
- The Phase 2 clinical data of the Bria-IMT regimen focused on 54 advanced metastatic breast cancer patients who failed multiple prior treatments including antibody drug conjugates
- BriaCell Therapeutics Corp. (TSX:BCT) opened trading at C$2.05
BriaCell Therapeutics (TSX:BCT) will present positive clinical data of Bria-IMT at the 2024 American Society of Clinical Oncology in Chicago.
The clinical-stage biotechnology company is presenting updated clinical data of its randomized Phase 2 study evaluating its lead product candidate, Bria-IMT in patients with advanced metastatic breast cancers.
The Phase 2 clinical data of the Bria-IMT regimen focused on 54 advanced metastatic breast cancer patients who failed multiple prior treatments including antibody drug conjugates. The study found a survival rate of a little more than four months.
The research found a median progression free survival rate of 3.9 months in patients treated with planned pivotal Phase 3 formulation is double the survival rate of patients in similar studies who received a physician’s treatment of choice. The overall response rate was said to compare favourably with the company’s existing literature.
“Patients with heavily pretreated metastatic breast cancer that have developed resistance to antibody drug conjugates face a very poor prognosis. Novel, well-tolerated and effective treatments remain a critical need,” Sara A. Hurvitz, MD, professor of medicine, Fred Hutchinson Cancer Center and University of Washington and BriaCell medical advisory board member, said in a news release. “Early data from the BriaCell study are quite promising and if confirmed in the larger clinical trial could be a game changer for patients.”
“Bria-IMT is a novel therapeutic which has the potential to address a major therapeutic challenge in the management of progressive metastatic breast cancer, and these early results with preliminary activity in a refractory patient setting are encouraging,” Adam M. Brufsky, MD, PhD, FACP, professor of medicine at the University of Pittsburgh School of Medicine and a member of BriaCell’s medical advisory board, added.
The 2024 American Society of Clinical Oncology takes place May 31-June 4 at McCormick Place in Chicago.
BriaCell Therapeutics is an immuno-oncology-focused biotechnology company specializing in targeted immunotherapies for cancer. BriaCell is conducting a Phase II clinical trial of Bria-IMT in metastatic advanced breast cancer. BriaCell is developing Bria-OTS, a personalized off-the-shelf immunotherapy for cancer based on matching the patient’s human leukocyte antigen type. Enhanced cellular immunotherapies with enhanced potency are under development.
BriaCell Therapeutics Corp. (TSX:BCT) opened trading at C$2.05.
Join the discussion: Find out what everybody’s saying about this stock on the BriaCell Therapeutics Corp. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
